This case demonstrates that pharmacological weight loss with agents such as tirzepatide may offer a viable, nonoperative alternative for patients with obesity-related SEL, particularly those who are not ideal surgical candidates. Validation in larger studies is needed to assess long-term efficacy and help guide patient selection for pharmacological versus surgical approaches. https://thejns.org/doi/10.3171/CASE25886.
Tazhibi et al. (Mon,) studied this question.